InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis. PR Newswire (Press Release) 3h
Learn Why The Bull Case For Stoke Therapeutics Stock Could Change Following Phase III Trial Progress Simply Wall St 21h
Acumen’s Alzheimer’s drug fails in phase II; stock plummets BioWorld 3d Alzheimer's Health Article paywall
Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab Toronto Star 3d Consumer Electronics Philips Electronics
Ncb freezes 25 properties worth Rs 20 crore in inter-state pharmaceutical drug diversion case AniNews.in 19h India
